Horizon Pharma PLC (NASDAQ:HZNP) has been given a consensus recommendation of “Buy” by the fifteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $17.82.
Several research firms have weighed in on HZNP. Mizuho restated a “neutral” rating and set a $9.00 target price (down from $10.00) on shares of Horizon Pharma PLC in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $18.00 price target (up from $17.00) on shares of Horizon Pharma PLC in a research note on Thursday, August 10th. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Sunday. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Horizon Pharma PLC in a research note on Wednesday, September 27th.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can boosted its position in shares of Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 1,378 shares during the last quarter. Sheaff Brock Investment Advisors LLC boosted its position in shares of Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 500 shares during the last quarter. Family Management Corp acquired a new stake in shares of Horizon Pharma PLC in the second quarter worth approximately $131,000. Ballentine Partners LLC acquired a new stake in shares of Horizon Pharma PLC in the second quarter worth approximately $139,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Horizon Pharma PLC in the first quarter worth approximately $151,000. 82.32% of the stock is currently owned by institutional investors and hedge funds.
Horizon Pharma PLC (NASDAQ:HZNP) traded down 2.552% during trading on Wednesday, reaching $13.555. 1,455,486 shares of the company were exchanged. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The firm’s market capitalization is $2.21 billion. The stock has a 50 day moving average price of $13.09 and a 200 day moving average price of $12.69.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The firm had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. During the same period last year, the firm posted $0.56 EPS. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, analysts expect that Horizon Pharma PLC will post $1.07 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Horizon Pharma PLC (HZNP) Receives $17.82 Average PT from Analysts” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/16/horizon-pharma-plc-hznp-receives-17-82-average-pt-from-analysts.html.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.